Care before and after lung transplant and quality of life research.

AACN Clin Issues

Niehoff School of Nursing, Loyola University Medical Center, Building 105, Room 2859, 2160 S. First Avenue, Maywood, IL 60153, USA.

Published: May 2001

Lung transplantation is a growing surgical option for patients with end-stage lung and pulmonary vascular diseases. After completing an extensive evaluation and meeting the selection criteria, patients are listed for either single or bilateral-sequential lung transplantation. Immediate postoperative management requires detailed attention to fluid management, monitoring for infection, reperfusion injury, pulmonary hygiene, and pain management. Length of stay depends on the patient's condition before transplant and postoperative complications. Discharge from the hospital can be as early as 7 days after transplantation. Newer immunosuppressive medications offer more options for treating and preventing rejection. Advanced practice nurses, such as coordinators, case managers, nurse practitioners, and clinical nurse specialists, are uniquely positioned to play key roles in coordinating the care of transplant patients across settings and both before and after the transplant procedure. The perioperative needs of lung transplant patients and the impact of this complex procedure on the recipients' and family's quality of life merit further investigation by clinicians and researchers.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00044067-200105000-00003DOI Listing

Publication Analysis

Top Keywords

lung transplant
8
quality life
8
lung transplantation
8
transplant patients
8
transplant
5
care lung
4
transplant quality
4
lung
4
life lung
4
transplantation growing
4

Similar Publications

Cell therapy: A beacon of hope in the battle against pulmonary fibrosis.

FASEB J

January 2025

Stem Cell and Biotherapy Technology Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang, China.

Pulmonary fibrosis (PF) is a chronic and progressive interstitial lung disease characterized by abnormal activation of myofibroblasts and pathological remodeling of the extracellular matrix, with a poor prognosis and limited treatment options. Lung transplantation is currently the only approach that can extend the life expectancy of patients; however, its applicability is severely restricted due to donor shortages and patient-specific limitations. Therefore, the search for novel therapeutic strategies is imperative.

View Article and Find Full Text PDF

Multisociety endorsement of the 2024 European guideline recommendations on coronary revascularization.

Braz J Cardiovasc Surg

January 2025

Coronary Center, Department of Thoracic and Cardiovascular Surgery, Miller Family Heart, Vascular, & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, United States.

View Article and Find Full Text PDF

Interstitial lung disease (ILD) can lead to pulmonary hypertension (ILD-PH), worsening prognosis and increasing mortality. Diagnosing ILD-PH is challenging due to the limitations of imaging methods. Right heart catheterization (RHC) is the gold standard for diagnosing PH but is limited to ILD patients considered for lung transplantation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!